FDA Logo links to FDA home page Skip Navigation
U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website
horizonal rule
Dockets Management


Volume 3


Appendix A - Study by Professor Shaker Mousa, Ph.D. focusing on the effect of enoxaparin on TFPI endothelial cell release inhibition induced by the bacterial endotoxin lipolysaccharide (LPS)

Appendix B - Study conducted by Drs. Michel Samama and Ismael Elalamy of Hotel-Dieu Hospital in Paris, France, revealing that enoxaparin has a process dependent inhibitory effect on Factor VIIa generation.

Appendix C - Study by Dr. Christian Boudier of Laboratoire d’Enzymologie in Illkirch, France measuring the
change of fluorescence of ATIII upon its complexation with different oligosaccharides and more particularly with decasaccharides isolated from enoxaparin.

Appendix D - Study by Professor von Specht comparing the FGF2 inhibiting effects of three groups of compounds: oligosaccharides with the 1,6-anhydro ring structure, oligosaccharides without the 1,6-anhydro ring structure, and a third group consisting of heparin, enoxaparin, and an ultra low molecular weight heparin

References Published Material

Top | Back

Page last updated October 11, 2005 RSChorizonal rule
Dockets Home Page | Dockets Contacts and Location | Operating Status | Item Code Definitions | Federal Register
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA

FDA/Dockets Management